Your guide to J-codes in medical billing, and what they can hide

An employer’s specialty trend was running at double digits, driven largely by therapies like Ocrevus, Darzalex Faspro, and Keytruda. When Leap ran a claims analysis on the employer’s data, it found markups as high as 400% over acquisition cost, with some members’ medications marked up by as much as $250,000 a year.

None of that markup appeared as its own line on a claim. It sat inside the allowed amount on the J-code line of the claim, which told the employer which drug was given and the total bundled cost of the drug. It doesn’t tell the employer what the drug itself cost.

This post breaks down your key questions around J-codes, such as: 

• What are J-codes, and how do they differ from Q-codes?
• What can a J-code claim hide?
• How can a claims-based analysis let benefits leaders and consultants see what is being paid for in specialty medicine?

What are J-codes in medical billing?

J-codes are Healthcare Common Procedure Coding System (HCPCS) Level II billing codes that identify a drug administered by a healthcare professional, such as an infusion or injection, that is billed on the medical benefit. Each J-code specifies the drug and the billing unit it’s billed in, such as 1 mg or 10 mg.

Specialty infusions are typically covered by the medical benefit, since a healthcare professional administers them in a clinical setting, such as a hospital outpatient department (HOPD). As a result, these drugs don’t typically flow through the pharmacy benefit manager. They often flow through medical claims as J-codes.

Each J-code is billed in units standardized for that particular drug.  In the example below, Ocrevus is billed in 1 mg increments whereas Remicade is billed in 10 mg increments.  The number of units on the claim equals the total dose administered.  The number of units that a patient needs is determined by their prescribing physician and can be based on a number of factors specific to their treatment such as weight.  

A J-code standardizes what was given and how much, but it does not ensure clarity in terms of how much the drug cost or how much the drug cost was marked up after acquisition.

What a J-code claim shows, and what it might be hiding

HOPDs and provider clinics commonly bill specialty drugs under a model called buy-and-bill. The provider buys the drug, administers it, and then bills the health plan for the drug at a contracted rate that’s often well above what the provider paid to acquire it. That difference is the provider’s margin, and the provider’s revenue depends on it.

Leap also bills the drug through the medical benefit, but at true acquisition cost, with no markup. Leap is paid through separate, itemized fees for clinical administration and care coordination, so its revenue doesn’t depend on the price of the drug.

On most claims, the drug is billed on its own J-code line, separate from administration and facility fees. The markup sits inside that line: the allowed amount reflects the contracted price for the drug, not what the provider paid for it. The employer plan sees the code, the units, and the amount paid, but it can’t see the acquisition cost or how much was added on top. A self-funded employer plan bears that cost directly, yet the claim gives it no way to see the difference.

Some contracts make the picture even less clear. When a hospital is paid a case rate or a per-visit rate, the drug, administration, and facility fees can be rolled into a single payment that the plan can’t break apart. Those arrangements are less common and depend on the network’s contract with the provider.

Site-of-care programs try to address the problem by steering members from the hospital to a lower-cost setting. That typically brings the markup down but doesn’t necessarily eliminate it altogether. 

As Leap Co-Founder and Chief Commercial Officer Rob LaHayne puts it plainly: “You’re sending patients from one provider marking the drug up 200 to 300% to a provider marking it up 50 or 60%. There’s still fundamentally a markup on the drug.”

What are Q-codes, and how are they different from J-codes?

Q-codes are temporary HCPCS Level II codes. They’re assigned when a new product needs a billing code before a permanent one exists. In specialty infusion, Q-codes appear frequently  on biosimilars (biologics the FDA has found to be highly similar to an FDA-approved reference product with no clinically meaningful difference). 

For employers, the practical difference is small. J-codes and Q-codes appear the same way on a medical claim, and under buy-and-bill, the allowed amount on either one reflects the contracted price for the drug rather than what the provider paid to acquire it.

How to see your specialty medicine costs inside J-code claims

A claims-level view can help you see what you’re actually paying for specialty drugs. Here are four steps to get there:

1. Pull medical-benefit claims by J-code and Q-code. Request your deidentified paid claims data from your carrier or third-party administrator, filtered to provider-administered drug codes. 
2. Normalize to billing units and match each line to an NDC. The National Drug Code (NDC) identifies the exact product: manufacturer, strength, and package size. Matching NDCs to J-code lines turns a code-level total into a product-level record you can price.
3. Benchmark against acquisition cost. Compare what was billed per unit against ASP, the average price manufacturers report to CMS after discounts. ASP is a benchmark and not what any individual provider paid. Commercial allowed amounts that run several multiples above ASP might indicate that there’s an embedded markup.
4. Find the drugs and members driving the trend. Based on Leap’s analysis, specialty infusion spend is highly concentrated: 1 to 2% of members typically drive 10 to 15% of total healthcare cost. Working with a benefits solution like Leap can allow you to better understand which members and what specialty drugs are driving significant unncessary spend.

Many employers can’t complete all four steps on their own. A claims-based savings analysis can help fill that gap.

How Leap delivers transparency

Leap structurally changes how specialty drugs are billed, so the markup is eliminated. Leap operates inside the existing medical benefit as a custom network provider and bills each encounter in three transparent parts:

Leap takes no margin on the drug. Leap doesn’t charge a per-member-per-month fee, an implementation fee, or a platform fee. Leap is paid only when care is delivered. 

Members keep the same plan, ID card, and coverage. The health plan keeps full control of prior authorization, utilization management, and medical necessity decisions. 

The claim still moves through the same medical-benefit process. It simply shows the employer what each part of the encounter costs.

How can J- and Q-codes be matched to NDCs?

Leap completes claims-based impact analyses on behalf of employers. This type of analysis maps J- and Q-codes to the NDC and the encounter line items to estimate potential savings. Each analysis is from an employer’s own deidentified claims data, quantifying the dollar opportunity drug by drug and member by member. 

The impact analysis sets the foundation for what savings could look like with Leap, so the number a benefits leader brings to their CFO or board of directors is a number that can be audited against paid claims after the fact.

How do vendors prove savings on encounters like Ocrevus or Remicade?

Encounter math only proves savings if it can be audited. Savings are auditable when the employer can trace each one back to its own paid claims and see the J-code, the units, the NDC, the acquisition cost, and the difference. 

When you evaluate any vendor that claims to reconcile J-code line items into encounter-level savings, a few questions separate real repricing from a marketing estimate:

• Is the analysis built on your claims data, or on a benchmark population?
• Does it show acquisition cost at the NDC level for each drug?
• Can you audit realized savings against paid claims once the program is live?
• How does the vendor get paid, and does any of its revenue depend on margin on the drug itself?

What about the employer at the start of this blog post? 

Six months after launching Leap, that employer is seeing $400,000 in annualized savings per 10,000 covered lives and projects $800,000 per 10,000 lives by year-end. One member now receives the same Gammagard infusion at home, on a schedule built around her needs, with no copay.

Please note: Results vary based on employer, plan design, and member population. 

What’s hiding in your J-codes?

The employer in this story couldn’t see drug pricing inside claims that recorded every infusion accurately and priced none of them transparently. All too often, a J-code tells you which drug was given, but a claims-level analysis tells you what that drug cost and what you and your plan can save.

Request a claims-based savings analysis to see what your J-code claims are hiding.

FAQs

Is a J-code the same as an NDC?

No. A J-code identifies a drug and its billing unit for medical billing purposes. An NDC identifies the exact product, including its manufacturer, strength, and package size. The two often appear together on the same claim line.

Are J-codes billed on the medical benefit or the pharmacy benefit?

J-codes are billed on the medical benefit, because they cover drugs administered by a healthcare professional. That’s why most specialty infusion spend does not appear in PBM reporting.

Can employers see drug cost on a standard J-code claim?

Usually not. Under buy-and-bill, the allowed amount on the drug line includes the provider’s markup over acquisition cost, so the employer sees the total without its parts.

Does itemizing the claim change my carrier, plan, or prior authorization process?

No. Leap coordinates care within the existing medical benefit. Members keep their plan and ID card, and the health plan retains full control of prior authorization and utilization management.

What data does a claims-based savings analysis require?

Typically, it requires paid medical claims that include J-code and Q-code lines, units, NDCs where available, and site-of-care information. Leap uses that data to estimate what each encounter would cost at true acquisition cost.